MEDICAMEQ · NSE
Medicamen Biotech Limited
₹346.3
+0.23% (+₹0.8)
Prev. close
₹345.5
Volume
1,28,639
Delivery %
47.7%
As of
17 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajesh Madan B. Pharma
Headquarters
New Delhi
Employees
405
Website
medicamen.comExchange
View on NSE ↗Key stats
Market cap
₹469.68 Cr
P/E ratio (TTM)
47.5
Dividend yield
0.29%
EPS (TTM)
₹7.29
Beta (1Y · daily vs NIFTY 50)
0.90
Beta (5Y · monthly vs NIFTY 50)
0.96
Shares float
54.19 L
EPS · quarter ended Jun 2026
₹1.36
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹112.72 Cr | ₹115.45 Cr | ₹140.87 Cr | ₹179.31 Cr | ₹162.55 Cr | ₹197.77 Cr | |
| EBITDA | ₹19.98 Cr | ₹25.27 Cr | ₹26.33 Cr | ₹24.57 Cr | ₹20.10 Cr | ₹22.70 Cr |
| ₹12.13 Cr | ₹14.90 Cr | ₹14.84 Cr | ₹10.93 Cr | ₹7.11 Cr | ₹9.64 Cr | |
| Diluted EPS | ₹9.93 | ₹12.19 | ₹11.82 | ₹8.63 | — | ₹7.11 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹194.00 Cr | ₹226.00 Cr | ₹279.00 Cr | ₹295.00 Cr | ₹297.00 Cr | ₹372.00 Cr | |
| — | — | ₹25.71 Cr | ₹31.11 Cr | ₹33.77 Cr | ₹47.78 Cr | |
| Stockholders' equity | ₹133.00 Cr | ₹146.00 Cr | ₹194.00 Cr | ₹207.00 Cr | ₹213.00 Cr | ₹276.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated. CWIP has no filed figures within the years shown — left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹4.11 Cr | ₹-6.29 Cr | ₹-6.74 Cr | ₹-8.16 Cr | ₹-33.17 Cr | |
| Investing cash flow | — | ₹-8.47 Cr | ₹-5.88 Cr | ₹-5.56 Cr | ₹-1.40 Cr | ₹-3.04 Cr |
| — | ₹4.30 Cr | ₹29.13 Cr | ₹6.31 Cr | ₹-1.47 Cr | ₹63.72 Cr | |
| Capital expenditure | ₹-17.97 Cr | ₹-8.61 Cr | ₹-6.60 Cr | ₹-6.29 Cr | ₹-2.19 Cr | ₹-4.78 Cr |
| End cash position | ₹3.89 Cr | ₹3.82 Cr | ₹20.78 Cr | ₹14.79 Cr | ₹3.76 Cr | ₹31.26 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Jun 22(3Q) | Sep 22–Mar 24(8Q) | Jun 24–Dec 24(3Q) | Mar 25 | Apr 25–Jun 26(6Q) |
|---|---|---|---|---|---|---|
| Promoter | 44.83% | 43.60% | 43.21% | 42.99% | 43.16% | 40.46% |
| Public | 55.17% | 56.40% | 56.79% | 57.01% | 56.84% | 59.54% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| Medicamen Biotech Limited | ₹469.68 Cr | ₹346.3 | 47.5 | 1.70 | 3.5% | 0.17 | +21.7% | +6.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.